PD-L1 as a Potential Target in Cancer Therapy (Review)
Introduction. Cancer is one of the most serious and common diseases with a high level of mortality. Due to this reason the searching of new directions and methods of cancer treatment is becoming more and more important with each passing year. Significant advances in cancer immunotherapy have been re...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2021-02-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243998628085760 |
|---|---|
| author | N. N. Andrusova M. A. Kolganova A. V. Aleshina I. E. Shohin |
| author_facet | N. N. Andrusova M. A. Kolganova A. V. Aleshina I. E. Shohin |
| author_sort | N. N. Andrusova |
| collection | DOAJ |
| description | Introduction. Cancer is one of the most serious and common diseases with a high level of mortality. Due to this reason the searching of new directions and methods of cancer treatment is becoming more and more important with each passing year. Significant advances in cancer immunotherapy have been reached over the past few decades. Moreover, an inhibition of the interaction between the programmed cell death receptor (PD-1) and its ligand (PD-L1), is sure to be perspective direction of the immuno-oncological therapy development.Text. PD-1/PD-L1 interaction plays a pivotal role in negative regulation of immune system, that protects host’s cells and tissues from the excessive immune response. However, it is also used by tumor cells to avoid the host's immune system. The discovery of this mechanism led to the development of inhibiting PD-1 or PD-L1 agents that enhance anti-tumor immunity. Meanwhile, anti-PD-L1 agents provide less toxicity in comparison with anti-PD-1 agents. FDA currently approved Atesolizumab, Durvalumab, and Avelumab PD-L1 inhibitors for cancer treatment. These agents demonstrated effective response during the clinical trials, however, they are used for a limited number of oncological diseases. In addition, BMS-936559 is a promising agent that had passed the first stage of the clinical trials. Nevertheless, immunotherapy involving PD-L1 inhibitors is closely related to a vast number of severe side effects including immune-mediated effects caused by the inhibition of PD-L1 ligands located on healthy cells. In these terms, the development of new agents deprived of these disadvantages is the reason for further studies.Conclusion. Immunotherapy in cancer uncovers new perspectives in treatment of refractory to standard therapies forms of cancer. And the development of new and improvement of existing PD-L1 blocking agents are of great importance in fighting against tumoral diseases. |
| format | Article |
| id | doaj-art-85bba9ec4f854e7ab2df74e90499216f |
| institution | Kabale University |
| issn | 2305-2066 2658-5049 |
| language | Russian |
| publishDate | 2021-02-01 |
| publisher | LLC Center of Pharmaceutical Analytics (LLC «CPHA») |
| record_format | Article |
| series | Разработка и регистрация лекарственных средств |
| spelling | doaj-art-85bba9ec4f854e7ab2df74e90499216f2025-08-20T03:59:17ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492021-02-01101313610.33380/2305-2066-2021-10-1-31-36808PD-L1 as a Potential Target in Cancer Therapy (Review)N. N. Andrusova0M. A. Kolganova1A. V. Aleshina2I. E. Shohin3Federal State Budget Educational Institution of Higher Education "MIREA – Russian Technological University"LLC "CPHA"LLC "CPHA"LLC "CPHA"Introduction. Cancer is one of the most serious and common diseases with a high level of mortality. Due to this reason the searching of new directions and methods of cancer treatment is becoming more and more important with each passing year. Significant advances in cancer immunotherapy have been reached over the past few decades. Moreover, an inhibition of the interaction between the programmed cell death receptor (PD-1) and its ligand (PD-L1), is sure to be perspective direction of the immuno-oncological therapy development.Text. PD-1/PD-L1 interaction plays a pivotal role in negative regulation of immune system, that protects host’s cells and tissues from the excessive immune response. However, it is also used by tumor cells to avoid the host's immune system. The discovery of this mechanism led to the development of inhibiting PD-1 or PD-L1 agents that enhance anti-tumor immunity. Meanwhile, anti-PD-L1 agents provide less toxicity in comparison with anti-PD-1 agents. FDA currently approved Atesolizumab, Durvalumab, and Avelumab PD-L1 inhibitors for cancer treatment. These agents demonstrated effective response during the clinical trials, however, they are used for a limited number of oncological diseases. In addition, BMS-936559 is a promising agent that had passed the first stage of the clinical trials. Nevertheless, immunotherapy involving PD-L1 inhibitors is closely related to a vast number of severe side effects including immune-mediated effects caused by the inhibition of PD-L1 ligands located on healthy cells. In these terms, the development of new agents deprived of these disadvantages is the reason for further studies.Conclusion. Immunotherapy in cancer uncovers new perspectives in treatment of refractory to standard therapies forms of cancer. And the development of new and improvement of existing PD-L1 blocking agents are of great importance in fighting against tumoral diseases.https://www.pharmjournal.ru/jour/article/view/896pd-l1 inhibitorimmune checkpoint blockadecancer immunotherapyatezolizumabdurvalumabavelumabmonoclonal antibody |
| spellingShingle | N. N. Andrusova M. A. Kolganova A. V. Aleshina I. E. Shohin PD-L1 as a Potential Target in Cancer Therapy (Review) Разработка и регистрация лекарственных средств pd-l1 inhibitor immune checkpoint blockade cancer immunotherapy atezolizumab durvalumab avelumab monoclonal antibody |
| title | PD-L1 as a Potential Target in Cancer Therapy (Review) |
| title_full | PD-L1 as a Potential Target in Cancer Therapy (Review) |
| title_fullStr | PD-L1 as a Potential Target in Cancer Therapy (Review) |
| title_full_unstemmed | PD-L1 as a Potential Target in Cancer Therapy (Review) |
| title_short | PD-L1 as a Potential Target in Cancer Therapy (Review) |
| title_sort | pd l1 as a potential target in cancer therapy review |
| topic | pd-l1 inhibitor immune checkpoint blockade cancer immunotherapy atezolizumab durvalumab avelumab monoclonal antibody |
| url | https://www.pharmjournal.ru/jour/article/view/896 |
| work_keys_str_mv | AT nnandrusova pdl1asapotentialtargetincancertherapyreview AT makolganova pdl1asapotentialtargetincancertherapyreview AT avaleshina pdl1asapotentialtargetincancertherapyreview AT ieshohin pdl1asapotentialtargetincancertherapyreview |